These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11381568)

  • 1. On sample size calculation in bioequivalence trials.
    Chow SC; Wang H
    J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):155-69. PubMed ID: 11381568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A note on sample size determination for bioequivalence studies with high-order crossover designs.
    Chen KW; Chow SC; Li G
    J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
    Yu YP; Yan XY; Yao C; Xia JL
    Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinded sample size re-estimation in crossover bioequivalence trials.
    Golkowski D; Friede T; Kieser M
    Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.
    Shen M; Russek-Cohen E; Slud EV
    Pharm Stat; 2015; 14(2):95-101. PubMed ID: 25477145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size determination in bioequivalence studies using statistical assurance.
    Ring A; Lang B; Kazaroho C; Labes D; Schall R; Schütz H
    Br J Clin Pharmacol; 2019 Oct; 85(10):2369-2377. PubMed ID: 31276603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On sample size calculation based on odds ratio in clinical trials.
    Wang H; Chow SC; Li G
    J Biopharm Stat; 2002 Nov; 12(4):471-83. PubMed ID: 12477070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size calculation for bioequivalence studies with high-order crossover designs.
    Qu RP; Zheng H
    Control Clin Trials; 2003 Aug; 24(4):436-9. PubMed ID: 12865037
    [No Abstract]   [Full Text] [Related]  

  • 10. An approach for sample size determination of average bioequivalence based on interval estimation.
    Chiang C; Hsiao CF
    Stat Med; 2017 Mar; 36(7):1068-1082. PubMed ID: 28070984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination for equivalence assessment with multiple endpoints.
    Sun A; Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1203-14. PubMed ID: 25032845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carryover negligibility and relevance in bioequivalence studies.
    Ocaña J; Sanchez O MP; Carrasco JL
    Pharm Stat; 2015; 14(5):400-8. PubMed ID: 26175204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A note on sample size calculation for mean comparisons based on noncentral t-statistics.
    Chow SC; Shao J; Wang H
    J Biopharm Stat; 2002 Nov; 12(4):441-56. PubMed ID: 12477068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs'.
    Yan Z
    Stat Med; 2013 Dec; 32(30):5484-6. PubMed ID: 24302283
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Authors' reply to Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs".
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5487-8. PubMed ID: 24302284
    [No Abstract]   [Full Text] [Related]  

  • 17. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
    Rasmussen HE; Ma R; Wang JJ
    Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-stage designs for cross-over bioequivalence trials.
    Kieser M; Rauch G
    Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical aspects of bioequivalence testing between two medicinal products.
    Zintzaras E
    Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):41-6. PubMed ID: 16010860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.